Altogether, our findings provide a more comprehensive depiction of how EBV exacerbates intestinal inflammation within a mouse model of IBD and the role of TLR9 inhibition in mitigating the clinical severity of the disease, as evidenced by lower DAI and damage scores, as well as longer colon lengths. This evidence concerns the gene TLR9 and inflammatory bowel disease.